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IntroductIon
Parkinson’s disease (PD) is one of the most common 
neurodegenerative diseases. Approximately 1-2% of 
the population over the age of 65 years suffers from 
PD, while this percentage arises to 3-5% at ages above 
85 years1. PD is characterized by motor symptoma-
tology including tremor at rest, rigidity, bradykinesia, 
postural instability and freezing episodes. However, 
the clinical spectrum of PD is more extensive cover-
ing a wide range of non motor symptoms, including 
cognitive and behavioral symptoms, sleep disorders, 
autonomic symptoms, sensory symptoms and fatigue1. 
The pathological hallmarks of the disease are the loss 
of the dopaminergic neurons in the substantia nigra, 
causing dopamine depletion in the striatum, and the 
presence of Lewy bodies in the remaining neurons. 
PD occurs primarily in a sporadic form, although 
family studies in patients with PD have highlighted 
specific genes/loci associated with the disease, follow-
ing an autosomal dominant or an autosomal recessive 
mode of inheritance. So far, PD has been associated 
with 15 genetic loci, however only five genes are defi-
nitely considered to be associated with the Mendelian 
inheritance of the disease2. One of the major genes as-
sociated with autosomal dominant PD is the Leucine-
Rich Repeat Kinase 2 (LRRK2, also referred to as 
PARK8) gene the discovery of which was a milestone 
in the genetic history of PD. This review describes the 
main data on the LRRK2 gene and PD, with particular 
emphasis on the G2019S mutation, which is the most 
common LRRK2 mutation identified today. It also 
discusses the structural features of the LRRK2 pro-
tein, its function, the effects of LRRK2 mutations and 
the possible substrates of LRRK2 and the pathways in 
which it may participate.
LrrK2 gene: g2019S mutatIon
The LRRK2 gene is located on chromosome 12q12, 
spans 144 Kb and contains 51 exons. In 2004 the first 
mutations in the LRRK2 gene were described, being 
now the most common genetic cause of both the hered-
itary and the sporadic form of the disease2. Although 
a large number of genetic changes is found through-
out the whole gene, only in five LRRK2 mutations 
(R1441C, R1441G, Y1699C, G2019S and I2020T) 
the pathogenesis is fully established3. Of particular 
interest is the LRRK2 6055G→A transition, result-
ing in a glycine-to-serine substitution at amino acid 
position 2019 (G2019S), which is currently the most 
common LRRK2 mutation and is associated with both 
the hereditary and the sporadic form of the disease. 
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Its incidence varies according to ethnicity, reaching 
very high levels in certain populations. In Europe, the 
G2019S mutation occurs at a rate of 2-5% in patients 
with inherited PD and of 1-2% in patients with spo-
radic PD2. Nevertheless, in some Asian countries4,5, 
in South Africa6 and in some European countries like 
Poland, Germany and Greece7-9, the incidence of the 
G2019S mutation is very rare to zero. Instead, the 
G2019S mutation is found in particularly high per-
centages in populations such as North Africa (37% 
and 41% in patients with hereditary and sporadic PD, 
respectively) and the Jewish population (Ashkenazi 
Jews) (29% and 13% in patients with hereditary and 
sporadic PD, respectively)10,11.
The G2019S mutation is likely to come from at 
least three different haplotypes2. Most patients with 
PD having this mutation live in different countries of 
Europe and North Africa, or belong to the Ashkenazi 
Jews population and seem to share a common founder 
haplotype (haplotype 1) suggested to have been creat-
ed in the Middle East about 2000 years ago2. A second 
haplotype is also found in some European patients, 
and a third-one is found in patients from Japan2.
Of particular interest is the penetrance of the 
G2019S mutation, which has been found to increase 
from 17% at age 50 years to 85% at age 70 years12. 
Nevertheless, in subsequent studies these percentag-
es vary in regard to the sample size of the study and 
the methodology used2. According to a major study 
involving 21 centres in North America and Europe, 
the penetrance of the G2019S mutation is age-depen-
dent, with rates of 28% at age 59 years, 51% at age 
69 years and 74% at age 79 years, and is independent 
of sex13. However, ethnicity may influence the pen-
etrance of the G2019S mutation which has been cal-
culated at 45% in Arabs14, while in Eskenazi Jews or 
Italians it was 35%11,15. This diversity of results may 
be explained by factors such as the fact that families 
with many members suffering from PD are overrepre-
sented, resulting in an overestimation of the G2019S 
penetrance16. Additional genetic or environmental fac-
tors may also influence the penetrance of the G2019S 
mutation16.
LrrK2 ProteIn (dardarIn)
The LRRK2 gene encodes a protein named dardarin17, 
a very large protein consisting of 2527 amino acids 
(286 KD) which belongs to the ROCO superfamily 
of proteins (18). LRRK2 protein is characterized by 
the presence of multiple functional domains: (i) the N-
terminal ankyrin (ΑΝΚ) domain (ii) the leucine-rich 
repeat (LRR) domain (iii) the Roc (Ras of complex 
protein) domain sharing sequence homology to the 
Ras-related GTPase superfamily (iv) the COR do-
main, C-terminal of the Roc domain (v) the kinase do-
main showing some homology to mitogen-activated 
protein kinase kinase kinase (MAPKKK) and (vi) the 
WD40 domain18. The simultaneous presence of a ki-
nase region and a GTPase region highlights the poten-
tial enzymatic function of the LRRK2 protein, while 
the presence of the ANK, LRR and WD40 domains 
indicates an increased likelihood of interaction of the 
LRRK2 protein with other proteins (18). The LRRK2 
protein is expressed in many regions of the central 
nervous system such as cortex, medulla, cerebellum, 
putamen and substantia nigra19. It is also expressed in 
other organs like heart, kidneys, lungs, liver and pe-
ripheral leukocytes19. Inside cells the LRRK2 protein 
is predominantly expressed in the cytoplasm and in a 
small percentage in the outer membrane of mitochon-
dria20. The LRRK2 protein has also been identified in 
structures such as plasma membrane, Golgi appara-
tus, cytoskeleton proteins, synaptic vesicles and lipid 
rafts20.
The physiological function of LRRK2 protein is 
not yet clear and current data are primarily derived 
from its complex structure and indirectly through the 
functional effects of LRRK2 mutations. The struc-
ture of the LRRK2 protein is of particular interest. As 
mentioned before LRRK2 belongs to the ROCO su-
perfamily of proteins which are characterized by the 
simultaneous presence of ROC-COR regions, while 
some of them, though not all, harbour an additional 
kinase region18. As a kinase, LRRK2 functions as 
serine/threonine kinase and has the ability to auto-
phosphorylate21-23. The effect of LRRK2 as a GTPase 
has also been documented23-26. According to the cur-
rent data, the Roc domain appears to be sufficient for 
LRRK2 GTPase activity, independently of its kinase 
activity, as in experiments with kinase-dead mutants, 
GTP binding was maintained24-26. On the contrary, 
LRRK2 kinase activity appears to be depended on 
GTPase activity, as isolation of the MAPKKK region 
from the rest of the protein, resulted in the inactivation 
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of LRRK2 kinase activity24-26. Roc domain is likely to 
control the action of LRRK2 kinase activity through 
intramolecular regulation, as increased GTP binding 
in the Roc domain or decreased GTPase action has 
been found to increase LRRK2 kinase activity, where-
as the hydrolysis of GTP to GDP by GTPase leads to 
the inactivation of LRRK2 kinase23-26.
effectS of LrrK2 mutatIonS
Due to the complex structure of the LRRK2 protein 
and the simultaneous presence of Roc and MAPKKK 
regions which demonstrate the dual enzymatic activ-
ity of the protein (both as a kinase and as a GTPase), 
major attention has been focused on the effect of 
LRRK2 mutations on its enzymatic properties. Specif-
ically, multiple mutations have been identified in the 
LRRK2 kinase domain, including the most common 
G2019S mutation. The G2019S mutation is located 
in a hinge like region which connects the N-terminal 
and C-terminal lobe of the MAPKKK domain and lies 
between the Asp-Phe-Gly (DFG) and Ala-Pro-Glu 
(APE) amino acids, respectively. The configuration of 
this region may prevent access of LRRK2 substrates, 
possibly playing an important role in regulating the ac-
tion of LRRK2 as a kinase18. Importantly, the G2019S 
mutation has been found to increase LRRK2 kinase 
activity21,23,27,28, perhaps “unlocking” this region. It is 
of note that, the G2019S mutation has also an auto-
phosphorylation site whithin this region29. However, 
the impact of LRRK2 autophosphorylation is current-
ly under investigation. Similar results have been found 
for the I2020T mutation23,30, however in another study, 
this mutation was associated with reduced LRRK2 ki-
nase activity31. No change or increase in the kinase 
activity was found for the Y1699C28,31, R1441C or 
R1441G mutations21,23,28,31. This difference probably 
stems from different structures, expression systems 
and methodologies of the various experiments. How-
ever, in most of the studies it appears that LRRK2 mu-
tations, especially the G2019S mutation, increases the 
activity of LRRK2 compared to wtLRRK2 (wild type 
LRRK2). 
Of particular interest is also the study of LRRK2 
mutations in the Roc domain. It has been found that 
R1441C/G mutations reinforce the action of LRRK2 
as a kinase, prolonging GTP binding, thus reducing the 
action of GTPase25. Nevertheless, in other studies the 
LRRK2 kinase activity was not affected24,32 and the in-
fluence of LRRK2 mutations in GTP binding was low 
to negligible23-26. It is also of note, that the Roc region 
has been found to interact with itself and with other 
regions of the LRRK2 protein, forming a dimer29,33, 
whereas mutations in this region have been found to 
affect this interaction29,33. It is also worth mentioning 
that, the wtLRRK2 dimer has recently been found to 
possess greater kinase activity compared to its mono-
mer form and this more active form was enriched in 
the plasma membrane compared to the cytoplasm34.
LrrK2 SuBStrateS and PathwayS 
The recognition of substrates and proteins that inter-
act with LRRK2 and of pathways that LRRK2 is im-
plicated, is an important step in order to improve our 
understanding regarding the precise role of LRRK2 
in PD pathogenesis. A number of substrates and path-
ways have already been associated with LRRK2. 
However, their exact relationship with PD is currently 
under investigation. 
Some of the currently identified LRRK2-inter-
acting proteins are proteins functioning in the cy-
toskeleton and trafficking. LRRK2 has been found to 
phosphorylate moesin, member of the ERM family of 
proteins (ezrin, radixin, moesin) involved in anchor-
ing the actin cytoskeleton to the plasma membrane. 
The G2019S mutation was found to increase phos-
phorylation and binding of moesin to F-actin and the 
plasma membrane31. Interestingly, in a recent study35, 
increased ERM phosphorylation, due to the G2019S 
mutation, was associated with inhibition of neuronal 
development. Another protein that LRRK2 has been 
found to interact, is the elongation factor 1A (EF1A) 
protein36. In vitro, EF1A was found to reduce the activ-
ity of LRRK2 as a kinase, however LRRK2 GTPase 
activity was not affected36. The expression of the EF1A 
protein is wide at a cellular level and it is estimated that 
60% of that is associated with the cytoskeleton, inter-
acting with both microtubules and actin36. In the study 
of Gillardon et al. the in vitro interaction of LRRK2-
EF1A proteins was found to disrupt the stability of 
microtubules. Notably, LRRK2 has previously been 
documented to interact with microtubules37. More-
over, in a recent study the G2019S LRRK2 mutation 
was associated with dendrite degeneration through 
hyperphosphorylation of tau, a protein known to bind 
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to microtubules, by the GSK3-β kinase38. How these 
proteins participate in the “puzzle” of PD pathogen-
esis needs to be further investigated. LRRK2 has also 
been found to interact with the Rab5b protein. Rab5b 
is a small GTPase that regulates vesicle transport from 
the plasma membrane to endosomes39. When co-ex-
pressed with LRRK2, Rab5b was found to eliminate 
the negative effects of the intracellular overexpression 
of wtLRRK2, which led to decreased endocytosis. 
This observation supports a potential role of LRRK2 
in normal synaptic function40. 
Recently, LRRK2 has been found to interact with 
proteins encoded by genes associated with familial 
PD. LRRK2 kinase has been found to phosphorylate 
alpha-synuclein in residue Ser12941. Phosphorylation 
of Ser129 was higher for the G2019S mutation com-
pared to the wtLRRK241. In another study in trans-
genic mice42, overexpression of the LRRK2 protein 
resulted in rapid development of the neuropathology 
phenotype associated with the A53T alpha-synuclein 
mutation, reinforcing the possible action of the two 
proteins in a common functional pathway. LRRK2 
has also been shown to directly interact with parkin. 
Parkin promoted the formation of LRRK2 aggregates 
and LRRK2 influence parkin to act as a ligase27. In 
a recent study, in overexpression of the G2019S mu-
tant, parkin rescued dopaminergic neuron loss43. Fur-
ther studies regarding these two proteins are expected 
to further clarify this interaction. Apart from parkin, 
in a recent study LRRK2 was found to interact with 
PINK1 and DJ-1, as well44, however these data are 
preliminary and need to be further examined.
Another substrate of the LRRK2 kinase is the 4E-
BP protein (eIF4E-binding proteins)45. This protein 
forms a protein complex with the eIF4E protein (eu-
karyotic translation initiation factor 4E)45 inhibiting 
its activation and therefore protein synthesis. When 
phosphorylated by the LRRK2 kinase, 4E-BP is re-
leased from this complex, leading to protein overex-
pression, reduced resistance to oxidative stress and 
loss of dopaminergic neurons45. Nevertheless, accord-
ing to a recent study, 4E-BP is not a direct substrate 
for the LRRK2 kinase46.
In in vitro conditions, LRRK2 has also been found 
to interact with 14-3-3 proteins, small (28-33kDa) 
acidic polypeptides that form homo- and hetero-dim-
ers. In the study of Nichols et al. the 14-3-3 protein 
was found to bind to the amino terminus of LRRK2 
in residues Ser910 and Ser93547 influencing the stabil-
ity of LRRK2, perhaps via affecting dimer formation 
and LRRK2 kinase activity47. This connection is ham-
pered by LRRK2 mutations leading to the formation 
of inclusions47.
Members of the MAPKK family such as MKK 
3, 4, 6 and 7 proteins have also been recognized as 
substrates for the LRRK2 kinase, whereas mutations 
in the LRRK2 gene have been found to increase the 
binding and phosphorylation of MKK proteins48,49. 
These observations suggest that LRRK2 indeed func-
tions as a MAPKK.
The association of the LRRK2 protein with chap-
erones, have also been reported. More specifically, 
LRRK2, through the MAPKKK region, has been 
found to interact with Hsp90. Inhibition of Hsp90 
disrupted the Hsp90-LRRK2 complex, resulting in 
LRRK2 degradation via the proteosome, thus protect-
ing cells from the neurotoxic effect of the LRRK2 ki-
nase50. Furthermore, CHIP has been found to bind and 
ubiquinate LRRK2, promoting its breakdown by the 
proteasome and Hsp90 complex51. Overexpression of 
CHIP appeared to be protective towards the toxicity 
caused by LRRK2 mutations51. 
Focusing on LRRK2 pathways, one possible 
mechanism is the MAPK/ERK pathway. Through this 
pathway, wtLRRK2 has been documented to exert 
a protective role against oxidative stress, an ability 
which was reduced in LRRK2 mutations52. The activa-
tion of proteins involved in this pathway such as Src, 
Hsp27, and JNK was found decreased in PD patients 
compared to the healthy study group, an observation 
that might indicate that changes in this pathway are 
common in PD patients52. The exact role of LRRK2 
in the MAPK pathway is not yet clear. A recent study 
found that LRRK2 kinase phosphorylates a variety of 
MAPK kinases48, whereas the MAPK pathway has 
currently been associated with increased transcription 
and expression of alpha-synuclein53. 
The process of apoptosis has also been associated 
with the LRRK2 protein. Recently, Ho et al. found 
that mutations associated with PD increased the asso-
ciation of LRRK2 with FADD (Fas-associated protein 
with death domain), leading to activation of caspase 
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8 and apoptosis, resulting in neurodegeneration54. In 
contrast, inhibition of FADD or inactivation caspase 
8 was found to prevent neurodegeneration54. It is also 
interesting that in a previous study, LRRK2 mutations 
were associated with neurotoxicity due to mitochon-
drial dependent apoptosis, thus apoptosis through the 
release of cytochrome c and the activation of caspase 
355. In this study, a key role in the neurotoxicity of 
LRRK2 mutations was attributed to Apaf1 (Apoptotic 
peptidase activating factor 1), as ablation of Apaf1, 
led to the inhibition of the activation of caspase 3 and 
neurotoxicity55.
Of particular interest is the recent implication of 
the LRRK2 protein in the autophagy pathway56. More 
specifically, the R1441G mutation was associated 
with impaired autophagy and accumulation of vesicles 
with incompletely digested products. In contrast, in-
activation of LRRK2 resulted in increased activity of 
autophagy56. A previous study had also indicated the 
potential role of LRRK2 in autophagy, as the G2019S 
mutation was associated with neurite shortening and 
an increase in the presence of autophagy vesicles57. 
Autophagy seems to be involved in many neurologi-
cal diseases58, thus it is very important to investigate 
the precise role of LRRK2 in this pathway. 
An additional pathway recently associated with 
LRRK2 is Wnt, which plays an important role in the 
normal neuronal development and function. LRRK2 
was found to interact with proteins of the Dishevelled 
family (DVL1-3), which are key regulators of Wnt 
pathways59, generally involved in the regulation of 
small GTPases.
concLuSIon
Since the discovery of the LRRK2 gene and its rela-
tionship with autosomal dominant and sporadic PD, 
extensive research has been focused on LRRK2, in an 
attempt to elucidate its implication in the pathogenesis 
of the disease. However, this research effort is still in 
its infancy; unravelling the relationship of LRRK2 
with PD is a huge ongoing scientific challenge in the 
area of PD genetics.
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ΠΕΡΙΛΗΨΗ: Η ανακάλυψη του γονιδίου της πρωτεϊνικής κινάσης 2 πλούσιας σε επαναλήψεις λευκίνης (LRRK2) αποτέλεσε 
σταθμό στον τομέα της γενετικής της νόσου του Parkinson. Μεταλλάξεις σε ολόκληρο το γονίδιο έχουν συσχετισθεί τόσο με 
την κληρονομική όσο και με τη σποραδική μορφή της νόσου Parkinson, σε ασυνήθιστα υψηλά ποσοστά, με την μετάλλαξη 
G2019S να αποτελεί σήμερα τη πιο συχνή γενετική αλλαγή που έχει συσχετισθεί με τη νόσο. Στην παρούσα ανασκόπηση θα 
γίνει εκτενής αναφορά στη συγκεκριμένη μετάλλαξη, θα περιγραφεί επίσης η πολύπλοκη δομή και λειτουργία της πρωτεΐνης 
LRRK2, καθώς και τα έως τώρα δεδομένα σχετικά με τη συμμετοχή της στην παθογένεση της νόσου του Parkinson. 
Λέξεις Κλειδιά: Γονίδιο LRRK2, Μετάλλαξη G2019S, Κινάση LRRK2.
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